Skip to main content
HROW
NASDAQ Life Sciences

Harrow 10-Q: Record Q3 Revenue $99.3M, $9.8M Net Income; VEVYE Licensor Consent Risk on TYRVAYA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$31.9
Mkt Cap
$1.03B
52W Low
$25.76
52W High
$54.85
52W Position info
24% above low
Off High info
42% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

HROW sits 24% above its 52-week low of $25.76 on elevated volume (2.0× avg).

Summary

Harrow's Q3 10-Q confirms $99.3M revenue and $9.8M net income, but discloses a nine-month net loss of $35.1M, $27.4M of operating cash burn, and an unresolved VEVYE licensor consent issue that could force a TYRVAYA divestiture.


Key Events · Earnings and Guidance · HROW

  • Q3 Revenue Jumps to $99.3M

    Total revenue rose to $99,297,000 from $71,638,000 a year earlier, with VEVYE at $39,699,000 and TRIESENCE at $10,707,000; Q3 net income was $9,757,000, or $0.25 diluted per share.

  • Nine-Month Loss and Cash Burn

    Through September 30, 2026 the company posted a net loss of $35,115,000 and used $27,363,000 of cash in operations, versus $35,453,000 provided in the prior-year period, driven largely by a $38,970,000 receivables build.

  • VEVYE Licensor Consent Unresolved

    A new risk factor states the VEVYE licensor has not agreed the dry-eye exclusivity restriction permits TYRVAYA; absent an arrangement, Harrow may need to divest TYRVAYA within a period generally of twelve months and could still owe up to $70,000,000 in milestones unless assumed.

  • TYRVAYA 2027 Guidance

    Management expects TYRVAYA to contribute in excess of $30,000,000 of revenue in 2027 with approximately $20,000,000 of new annual operating expenses, and does not expect the first net sales milestone to be achieved.


Analysis · HROW · Life Sciences

The 10-Q confirms the swing to profitability the 8-K flagged this morning, but it also surfaces two things the headline release did not: a nine-month net loss of $35.1M with $27.4M of operating cash burn, and a new risk factor saying the VEVYE licensor has not agreed that its dry-eye exclusivity restriction permits the TYRVAYA acquisition. If that dispute is not resolved, Harrow may have to divest TYRVAYA within roughly twelve months while still owing up to $70M in contingent milestones unless a buyer assumes them. Against that, management guides TYRVAYA to more than $30M of 2027 revenue at a cost of about $20M in new annual operating expense.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HROW was trading at $31.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $25.76 to $54.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HROW - Latest Insights

HROW
Nov 09, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.14
Real-time Price: $31.41 info
Change: +$0.267 (+0.86%) info
Market Cap: $1.03B info
HROW
Nov 09, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $27.44
Real-time Price: $31.41 info
Change: +$3.97 (+14%) info
Market Cap: $1.03B info
HROW
Oct 05, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.90
Real-time Price: $31.41 info
Change: +$0.510 (+2%) info
Market Cap: $1.03B info
HROW
Aug 21, 2026, 12:09 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $41.61
Real-time Price: $31.41 info
Change: -$10.20 (-25%) info
Market Cap: $1.03B info
HROW
Aug 10, 2026, 4:28 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $40.05
Real-time Price: $31.41 info
Change: -$8.64 (-22%) info
Market Cap: $1.03B info